SKP alleviates the ferroptosis in diabetic kidney disease through suppression of HIF-1α/HO-1 pathway based on network pharmacology analysis and experimental validation

• Egile Nagusiak: Yangtian Yan (Egilea), Ningning Yuan (Egilea), Yuchi Chen (Egilea), Yun Ma (Egilea), Ali Chen (Egilea), Fujing Wang (Egilea), Shihua Yan (Egilea), Zhuo'en He (Egilea), Jinyue He (Egilea), Chi Zhang (Egilea), Hao Wang (Egilea), Mingqing Wang (Egilea), Jianxin Diao (Egilea), Wei Xiao (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2024-02-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Diabetic kidney disease (DKD) represents a microvascular complication of diabetes mellitus. Shenkang Pills (SKP), a traditional Chinese medicine formula, has been widely used in the treatment of DKD and has obvious antioxidant effect. Ferroptosis, a novel mode of cell death due t...